MedTrace Logo

CT 327 in the "Atopy Patch Test" Model

NCT01368315 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-06-07

No results posted yet for this study

Summary

A Randomized, Double-Blind, Phase I, Single-Center Study on the Efficacy and Safety of CT 327 in the Atopy Patch Test model.

Conditions

Interventions

DRUG

CT327 application

Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.

DRUG

Placebo

Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.

DRUG

Active comparator

Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.

DRUG

No intervention

No intervention to one out of four test fields marked on the patient's back.

Sponsors & Collaborators

  • Creabilis SA

    lead INDUSTRY

Principal Investigators

  • Prof. Dr. Med. Johannes Ring · Klinik und Poliklinik für Dermatologie und Allergologie Am Biederstein, Technische Universität München, Munich, Germany

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01368315 on ClinicalTrials.gov